Trial · NCT05042362
Adverse events90
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 90
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Elinzanetant 120 mg Week 1-12 | 14 | 199 | 14 |
| other | Fatigue | General disorders | Placebo Week 1-12 | 3 | 194 | 3 |
| other | Fatigue | General disorders | Elinzanetant 120 mg Week 13-26 | 0 | 171 | 0 |
| other | Fatigue | General disorders | Placebo - Elinzanetant 120 mg Week 13-26 | 1 | 168 | 1 |
| other | Fatigue | General disorders | Elinzanetant 120 mg Week 1-26 | 15 | 367 | 15 |
| other | Depression rating scale score increased | Investigations | Elinzanetant 120 mg Week 1-12 | 12 | 199 | 13 |
| other | Depression rating scale score increased | Investigations | Placebo Week 1-12 | 11 | 194 | 12 |
| other | Depression rating scale score increased | Investigations | Elinzanetant 120 mg Week 13-26 | 1 | 171 | 1 |
| other | Depression rating scale score increased | Investigations | Placebo - Elinzanetant 120 mg Week 13-26 | 2 | 168 | 2 |
| other | Depression rating scale score increased | Investigations | Elinzanetant 120 mg Week 1-26 | 14 | 367 | 16 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Elinzanetant 120 mg Week 1-12 | 10 | 199 | 10 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo Week 1-12 | 10 | 194 | 11 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Elinzanetant 120 mg Week 13-26 | 1 | 171 | 1 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo - Elinzanetant 120 mg Week 13-26 | 1 | 168 | 1 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Elinzanetant 120 mg Week 1-26 | 12 | 367 | 12 |
| other | Headache | Nervous system disorders | Elinzanetant 120 mg Week 1-12 | 14 | 199 | 14 |
| other | Headache | Nervous system disorders | Placebo Week 1-12 | 5 | 194 | 5 |
| other | Headache | Nervous system disorders | Elinzanetant 120 mg Week 13-26 | 4 | 171 | 4 |
| other | Headache | Nervous system disorders | Placebo - Elinzanetant 120 mg Week 13-26 | 6 | 168 | 7 |
| other | Headache | Nervous system disorders | Elinzanetant 120 mg Week 1-26 | 24 | 367 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05042362/events